Literature DB >> 19451420

Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in.

Michael J O'Connell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19451420     DOI： 10.1200/JCO.2009.22.2919

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

1.  Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?

Authors:  Fotios Loupakis; Alfredo Falcone
Journal:  Nat Rev Clin Oncol       Date:  2010-04       Impact factor: 66.675

2.  Fms-like tyrosine kinase 3 receptor ligand (Flt3L)-based vaccination administered with an adenoviral vector prevents tumor growth of colorectal cancer in a BALB/c mouse model.

Authors:  Carina Riediger; Gerhard Wingender; Percy Knolle; Sebastian Aulmann; Wolfgang Stremmel; Jens Encke
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-10       Impact factor: 4.553

Review 3.  [Multimodality therapy of colorectal cancer].

Authors:  U Hacker; M Hallek; S Kubicka
Journal:  Internist (Berl)       Date:  2010-11       Impact factor: 0.743

4.  Cytotoxic and Apoptotic Effects of the Combination of Borax (Sodium Tetraborate) and 5-Fluorouracil on DLD-1 Human Colorectal Adenocarcinoma Cell Line.

Authors:  Ömer Faruk Kırlangıç; Ecem Kaya-Sezginer; Sema Ören; Serap Gür; Özlem Yavuz; Taner Özgürtaş
Journal:  Turk J Pharm Sci       Date:  2022-08-31

5.  Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.

Authors:  Huang Zhijun; Wang Shusheng; Min Han; Li Jianping; Qin Li-Sen; Li Dechun
Journal:  Tumour Biol       Date:  2016-02-01

6.  A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.

Authors:  Christos A Papadimitriou; Pavlos Papakostas; Maria Karina; Lia Malettou; Meletios A Dimopoulos; George Pentheroudakis; Epaminontas Samantas; Aristotelis Bamias; Dimosthenis Miliaras; George Basdanis; Nikolaos Xiros; George Klouvas; Dimitrios Bafaloukos; Georgia Kafiri; Irene Papaspirou; Dimitrios Pectasides; Charisios Karanikiotis; Theofanis Economopoulos; Ioannis Efstratiou; Ippokratis Korantzis; Nikolaos Pisanidis; Thomas Makatsoris; Fotini Matsiakou; Gerasimos Aravantinos; Haralabos P Kalofonos; George Fountzilas
Journal:  BMC Med       Date:  2011-01-31       Impact factor: 8.775

7.  MicroRNA profiling in human colon cancer cells during 5-fluorouracil-induced autophagy.

Authors:  Ni Hou; Jia Han; Jie Li; Yingxun Liu; Yannan Qin; Lei Ni; Tusheng Song; Chen Huang
Journal:  PLoS One       Date:  2014-12-19       Impact factor: 3.240

8.  MicroRNA-423-5p inhibits colon cancer growth by promoting caspase-dependent apoptosis.

Authors:  Wenzhuo Jia; Tao Yu; Qi An; Xianglong Cao; Hongda Pan
Journal:  Exp Ther Med       Date:  2018-06-12       Impact factor: 2.447

9.  Biological predictors of survival in stage II colorectal cancer.

Authors:  Yoshitake Ueda; Kazuhiro Yasuda; Masafumi Inomata; Norio Shiraishi; Shigeo Yokoyama; Seigo Kitano
Journal:  Mol Clin Oncol       Date:  2013-05-20

10.  Preoperative serum CA 72.4 as prognostic factor of recurrence and death, especially at TNM stage II, for colorectal cancer.

Authors:  Daniel Ayude; Francisco Javier Rodríguez-Berrocal; José Ayude; Sonia Blanco-Prieto; Lorena Vázquez-Iglesias; Marta Vázquez-Cedeira; María Páez de la Cadena
Journal:  BMC Cancer       Date:  2013-11-12       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.